MX2022016004A - Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. - Google Patents
Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1.Info
- Publication number
- MX2022016004A MX2022016004A MX2022016004A MX2022016004A MX2022016004A MX 2022016004 A MX2022016004 A MX 2022016004A MX 2022016004 A MX2022016004 A MX 2022016004A MX 2022016004 A MX2022016004 A MX 2022016004A MX 2022016004 A MX2022016004 A MX 2022016004A
- Authority
- MX
- Mexico
- Prior art keywords
- mcl
- inhibitors
- pyrazol
- indole derivatives
- linked macrocyclic
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- UULFYKOEVQAAOU-UHFFFAOYSA-N N1N=CC=C1C1=CC=CC2=C1NC=C2 Chemical class N1N=CC=C1C1=CC=CC2=C1NC=C2 UULFYKOEVQAAOU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se relaciona con agentes farmacéuticos útiles para terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20181138 | 2020-06-19 | ||
| EP20203938 | 2020-10-26 | ||
| PCT/EP2021/066653 WO2021255257A1 (en) | 2020-06-19 | 2021-06-18 | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016004A true MX2022016004A (es) | 2023-04-11 |
Family
ID=76532217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016004A MX2022016004A (es) | 2020-06-19 | 2021-06-18 | Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230234969A1 (es) |
| EP (1) | EP4168412A1 (es) |
| JP (1) | JP2023530985A (es) |
| KR (1) | KR20230026357A (es) |
| CN (1) | CN115943147A (es) |
| AU (1) | AU2021291056A1 (es) |
| BR (1) | BR112022025674A2 (es) |
| CA (1) | CA3180903A1 (es) |
| MX (1) | MX2022016004A (es) |
| WO (1) | WO2021255257A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007008627A2 (en) | 2005-07-07 | 2007-01-18 | Abbott Laboratories | Apoptosis promoters |
| MX2009011211A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Indoles sustituidos en la posicion 7 inhibidores de mci-1. |
| US7981888B2 (en) | 2007-04-16 | 2011-07-19 | Abbott Laboratories | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives |
| WO2017182625A1 (en) | 2016-04-22 | 2017-10-26 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
| TW201904976A (zh) | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| AU2019347963A1 (en) | 2018-09-30 | 2021-05-27 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| WO2020103864A1 (en) | 2018-11-22 | 2020-05-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as mcl-1 inhibitors |
| US20220396587A1 (en) | 2019-01-23 | 2022-12-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| SG11202109367WA (en) | 2019-03-08 | 2021-09-29 | Zeno Management Inc | Macrocyclic compounds |
-
2021
- 2021-06-18 KR KR1020227045814A patent/KR20230026357A/ko unknown
- 2021-06-18 WO PCT/EP2021/066653 patent/WO2021255257A1/en unknown
- 2021-06-18 EP EP21733814.4A patent/EP4168412A1/en active Pending
- 2021-06-18 CN CN202180043419.3A patent/CN115943147A/zh active Pending
- 2021-06-18 CA CA3180903A patent/CA3180903A1/en active Pending
- 2021-06-18 MX MX2022016004A patent/MX2022016004A/es unknown
- 2021-06-18 BR BR112022025674A patent/BR112022025674A2/pt unknown
- 2021-06-18 JP JP2022577448A patent/JP2023530985A/ja active Pending
- 2021-06-18 AU AU2021291056A patent/AU2021291056A1/en active Pending
- 2021-06-18 US US18/001,352 patent/US20230234969A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230026357A (ko) | 2023-02-24 |
| AU2021291056A1 (en) | 2023-02-23 |
| EP4168412A1 (en) | 2023-04-26 |
| US20230234969A1 (en) | 2023-07-27 |
| BR112022025674A2 (pt) | 2023-01-17 |
| WO2021255257A1 (en) | 2021-12-23 |
| JP2023530985A (ja) | 2023-07-20 |
| CN115943147A (zh) | 2023-04-07 |
| CA3180903A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551274A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2023000438A (es) | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. | |
| EA202191801A1 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| MX2020006219A (es) | Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer. | |
| BRPI0514736A (pt) | inibidores do receptor sigma | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| MX2022004419A (es) | Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6. | |
| ZA201808562B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
| MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. | |
| MX2022016004A (es) | Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1. | |
| MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). | |
| MX2019004822A (es) | Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2022015998A (es) | Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1. | |
| MX2022010299A (es) | Derivados macrocíclicos de indol como inhibidores de mcl-1. | |
| MX2022015005A (es) | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. | |
| MX2023007291A (es) | Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1. | |
| MX2022011565A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2021015898A (es) | Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d. |